TARS
Tarsus Pharmaceuticals, Inc. Common Stock
stockNASDAQ
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 69.50 | 2026-10-19 | -1.91% | 0.083 |
| 1M | 75.69 | 2026-09-25 | -9.94% | 0.079 |
| 3M | 58.66 | 2026-07-24 | +16.21% | 0.559 |
| 6M | 61.45 | 2026-04-24 | +10.94% | 0.192 |
| 1Y | 66.06 | 2025-10-24 | +3.19% | 0.650 |
| 2Y | 39.41 | 2024-10-25 | +72.98% | — |
| 5Y | 28.48 | 2021-10-25 | +139.36% | 0.848 |
Tarsus Pharmaceuticals, Inc. Common Stock (NASDAQ:TARS) stock price today is $68.17, and today's volume is 556,620. TARS is down 5.425% today. The 30 day average volume is 908,084. TARS market cap is $3.19B with 46.79M shares outstanding.